

ASX Announcement



First Remplir™ Surgical Case Completed in U.S. Department of Defense Hospital Network Following Recent Approval

- First Remplir™ surgical case successfully completed within the U.S. Department of Defense (DoD) / Veterans Affairs (VA) hospital network.
- Rapid conversion of approval into clinical use following DoD / VA access announcement on 15 April 2026 enabling Remplir to be used in a network of 221 hospitals.
- Demonstrates early surgeon engagement and effectiveness of Orthocell's U.S. commercial and distributor footprint to deliver on new revenue opportunity.
- U.S. distribution partners to support further uptake of Remplir across the DoD and VA systems as part of its broader US commercialisation strategy.
- Important milestone in scaling U.S. revenues across military and veteran healthcare systems in addition to the broader rollout throughout the U.S. hospital system.

Perth, Australia; 17 April 2026: Regenerative medicine company Orthocell Limited (ASX: OCC, "Orthocell" or the "Company") is pleased to announce that the first surgical case using Remplir has been successfully completed within the U.S. Department of Defense (DoD) / Veterans Affairs (VA) hospital network, shortly after the Company announced approval to supply Remplir into these hospital systems.

This milestone marks the first clinical use of Remplir within the DoD / VA network and represents an important step in Orthocell's U.S. commercialisation strategy, demonstrating the Company's ability to rapidly translate regulatory and procurement approvals into real-world surgical adoption and revenue generation. The surgery was conducted at a military base hospital in Ohio.

As announced on 15 April 2026, Orthocell secured approval for Remplir to be supplied across the U.S. Department of Defense and Veterans Affairs hospital networks, providing access to approximately 51 DoD military hospitals and 170 VA medical centres nationwide.

The rapid completion of a first surgical case highlights early engagement from surgeons within these systems and reinforces the strength of Orthocell's existing U.S. distributor footprint, which spans 17 states and supports efficient onboarding and in-theatre case support. These distributors will now support further uptake of Remplir across the DoD and VA systems as part of Orthocell's broader US commercialisation strategy.

For personal use only

Orthocell Managing Director Paul Anderson said: “We are extremely pleased to see Remplir progress to its first surgical case within the U.S. DoD and VA hospital network so soon after approval, validating our commercial strategy, surgeon engagement, and distribution capability.

This milestone highlights both the clinical relevance of Remplir for complex nerve injuries and our ability to execute rapidly once access is secured. Military and veteran healthcare systems manage some of the most challenging trauma cases, and early surgical uptake is an encouraging signal as we continue to expand activity across these hospitals.”

The initial use of Remplir within the DoD / VA hospital network builds on Orthocell’s broader rollout of Remplir across the U.S. hospital system and the strong commercialisation progress being achieved to date. With expanding hospital access, growing surgeon engagement and increasing case activity, the Company continues to make excellent progress with its Remplir rollout across the U.S.

Orthocell will continue to work closely with its U.S. distribution partners and surgeon network to support further uptake of Remplir across the DoD and VA systems as part of its broader U.S. commercialisation strategy.

Release authorised by:

Paul Anderson
Orthocell Ltd CEO and MD

For more information, please contact:

General enquiries

Paul Anderson
Orthocell Limited
CEO and MD
P: +61 8 9360 2888
E: paul.anderson@orthocell.com

Media enquiries

Haley Chartres
H^CK Director
P: +61 423 139 163
E: haley@hck.digital

Investor enquiries

Shaun Duffy
VECTOR Advisors
P: +61 404 094 384
E: sduffy@vectoradvisors.au

About Orthocell Limited

ACN 118 897 135

Registered Office – Building 191 Murdoch University, 90 South Street, Murdoch WA 6150 Australia

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell's portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in the US, Australia, New Zealand, Singapore, UK, Europe, Canada and Brazil and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently gained clearance for use in the US. The Company has appointed a network of specialist US distributors and recorded initial sales. The Company's flagship nerve repair product is also approved in Australia, New Zealand and Singapore where it is distributed by Device Technologies Group. Other Remplir approvals include Thailand, Canada and Hong Kong. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company's other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.

For more information on Orthocell, please visit www.orthocell.com or follow us on Twitter @OrthocellLtd and LinkedIn www.linkedin.com/company/orthocell-ltd

Forward Looking Statement

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.